FALCON THERAPEUTICS
Falcon Therapeutics Chapel Hill-based biotechnology company .The company is focused on developing a treatment of brain cancer with autologous neural stems cells that seek out and destroy cancer cells. It has filed two patents. It was founded by Shawn Hingtgen, a professor in the Division of Molecular Pharmaceutics at the UNC-Chapel Hill Eshelman School of Pharmacy.
FALCON THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Chapel Hill, North Carolina, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
700 K USD
Current Employees Featured
Founder
More informations about "Falcon Therapeutics"
Anna Seal - SVP - GlaxoSmithKline | LinkedIn
Founder and CFO Falcon Therapeutics, Inc. · Experience: GlaxoSmithKline · Education: Penn State University · Location: Chapel Hill · 429 connections on LinkedIn. View Anna Seal’s …See details»
Falcon Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Falcon Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Nervous System Diseases, Neoplasms, Technology ...See details»
Falcon Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Falcon Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Falcon Therapeutics Inc. - VentureRadar
Falcon Therapeutics is developing an entirely new approach to Glioblastoma therapy that uses revolutionary stem cell technology to create personalized genetically engineered neural stem …See details»
Falcon™ - Alcyone Tx
Intra-CSF Drug & Delivery Optimization Dosing & delivering gene-based therapeutics to the brain with efficiency and precision is critical for successful treatment of complex neurological …See details»
Biogen and Alcyone Therapeutics Announce License and …
Jan 4, 2023 Alcyone leverages the synergy between Falcon™, the Company’s proprietary intrathecal precision dosing and biodistribution platform that incorporates deep knowledge of …See details»
Falcon Therapeutics, Inc. | SBIR.gov
Personalized Neural Stem Cell Therapy for Cancer Amount: $1,493,077.00 PROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to …See details»
Home - Alcyone Tx
Shining Brightly Together Alcyone takes its name from the brightest star in the Taurus constellation. Alcyone is not one single star, but a multiple star system with three components. …See details»
FALCON THERAPEUTICS, INC. in Durham, NC - Bizapedia
Feb 21, 2025 Discover Company Info on FALCON THERAPEUTICS, INC. in Durham, NC, such as Contacts, Addresses, Reviews, and Registered Agent.See details»
FALCON THERAPEUTICS, INC. Bankruptcy Filing Details
Sep 15, 2021 FALCON THERAPEUTICS, INC. Bankruptcy Date FALCON THERAPEUTICS, INC. filed a 7 chapter bankruptcy in the Eastern District of North Carolina bankruptcy court on …See details»
Bryn Martin, PhD - Alcyone Tx
Dr. Martin leads the Alcyone Therapeutics – Falcon™ Platform Research, Data Sciences and Bioinformatics group focused on advancement of our Precision Delivery portfolio. Dr. Martin …See details»
Home | DTx Pharma
Jul 17, 2023 DTx Pharma is a clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics.See details»
NEWS AND MEDIA – The Hingtgen Lab - TarHeels.live
Shawn Hingtgen, Falcon Therapeutics founder, pitches a creative cure for brain cancers – WRAL, 2018See details»
Similar companies to Falcon Therapeutics | VentureRadar
Companies like Falcon Therapeutics. Similar companies and competitors in the areas of Biotech, Biotechnology and more.See details»
Amasa Therapeutics - VentureRadar
Falcon Therapeutics Inc. USA n/a Falcon Therapeutics is developing personalized neural stem-cell therapies to treat brain tumors called glioblastoma. Hemispherian AS Norway n/a …See details»
DTx Pharma And The Near-Term Future Of RNA Therapeutics
Nov 21, 2022 FALCON consists of multiple naturally occurring fatty acids covalently coupled to siRNA that results in potent cellular uptake and improved bio-distribution. It enables …See details»
News | DTx Pharma
“We are incredibly excited to support the DTx Pharma team in their efforts to advance the FALCON platform and bring RNA therapeutics to tissues that were previously inaccessible to …See details»
Cidara Therapeutics to Participate in World Health Organization …
2 days ago Cidara Therapeutics (CDTX) announced its participation in a important World Health Organization (WHO) panel discussion on H5N1 influenza preparedness and response, …See details»
Establishing Canada’s first large-scale bioinnovation centre
2 days ago A one-of-a-kind facility in Canada, the Neptune BioInnovation Centre (NBC) will encourage biotechnology advancements in areas such as smart materials, bioplastics, …See details»
Cidara Therapeutics to Participate in World Health Organization …
2 days ago SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to …See details»